Dapivirine vs Emtricitabine/tenofovir disoproxil fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Dapivirine · Dapivirine Vaginal Ring

Marketed by Population Council and partners

Phase 3 in HIVsmall molecule
Reliable signal

NCT01617096 · Phase 3 · completed

This Phase 3 trial randomized 2,629 women to a monthly dapivirine vaginal ring or a placebo ring, with participants and investigators blinded, and used HIV-1 seroconversion as the primary endpoint. The published analysis shows a 27% lower incidence of HIV-1 infection with dapivirine (95% CI 1 to 46; P = 0.046). The design is robust and the primary comparison is statistically significant, although the effect was smaller where adherence was low.

Reported efficacy

Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. (minimum of 12 months and a maximum of 14 months per participant); The Number of Participants That Experienced Grade 2, 3, 4 and Serious Adverse Events Over the Investigational Product Used Period (25 mg Dapivirine Administered in a Silicone Elastomer Vaginal Matrix Ring (DVR), Inserted Once Every 4 Weeks). (minimum of 12 months and a maximum of 14 months per participant): HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007). (met)

Result source: NCT01617096

Emtricitabine/tenofovir disoproxil fumarate · Truvada

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Partial signal

NCT00323544 · Phase 3 · completed

This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07584122 (registry estimate)

Reported efficacy

The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)

Result source: NCT00323544

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointDapivirineEmtricitabine/​tenofovir disoproxil fumarate
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0625050483.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06250504—Not posted · NCT00323544
CD4 count, change (week 48)—Trial running · NCT06250504224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711

HIV-1 RNA below 50 copies/mL (week 48)

Dapivirine
—Trial running · NCT06250504
Emtricitabine/​tenofovir disoproxil fumarate
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510

HIV-1 RNA 50 copies/mL or more (week 48)

Dapivirine
—Trial running · NCT06250504
Emtricitabine/​tenofovir disoproxil fumarate
—Not posted · NCT00323544

CD4 count, change (week 48)

Dapivirine
—Trial running · NCT06250504
Emtricitabine/​tenofovir disoproxil fumarate
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dapivirine: 4 of 4 rows · Emtricitabine/tenofovir disoproxil fumarate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDapivirineEmtricitabine/​tenofovir disoproxil fumarate
Dropout rate
11.3%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
9.9%25 mg
NCT02862171 · Phase 3
3.6%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
5.5%
NCT02028338 · Phase 2 · registry result, not featured evidence
2.8%
NCT02010593 · Phase 2 · registry result, not featured evidence
20.9%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
23.3%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
10.5%
NCT03239483 · Phase 1 · registry result, not featured evidence
31%
NCT01539226 · Phase na · registry result, not featured evidence
24.7%a
NCT00458393 · Phase 3
show 15 more results
16%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
24%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
0%200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
24.2%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
79.9%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01195467 · Phase 3 · registry result, not featured evidence
19.5%
NCT00625404 · Phase 3 · registry result, not featured evidence
25.5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
8.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
—25 mg
NCT02862171 · Phase 3
—25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
—
NCT03593655 · Phase 2 · registry result, not featured evidence
—
NCT02028338 · Phase 2 · registry result, not featured evidence
—
NCT02010593 · Phase 2 · registry result, not featured evidence
4.7%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
—
NCT03239483 · Phase 1 · registry result, not featured evidence
0%
NCT01539226 · Phase na · registry result, not featured evidence
—a
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
8%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
—
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
1.6%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
7.4%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
—
NCT01195467 · Phase 3 · registry result, not featured evidence
—
NCT00625404 · Phase 3 · registry result, not featured evidence
5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
—NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
—NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
Serious AEs
8.8%25 mg DVR inserted once every 4 weeksa
NCT01617096 · Phase 3 · monotherapy
show 9 more results
2.1%25 mg
NCT02862171 · Phase 3
1.4%25 mg vaginal matrix ring
NCT02858037 · Phase 3 · registry result, not featured evidence
0%
NCT03593655 · Phase 2 · registry result, not featured evidence
2.7%
NCT02028338 · Phase 2 · registry result, not featured evidence
1.4%
NCT02010593 · Phase 2 · registry result, not featured evidence
2.3%Dapivirine Gel 4759
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%Dapivirine Gel 4789
NCT00799058 · Phase 1/2 · registry result, not featured evidence
0%
NCT03239483 · Phase 1 · registry result, not featured evidence
3.1%
NCT01539226 · Phase na · registry result, not featured evidence
7.5%a
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
0%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
7.7%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
0%Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
9.7%
NCT00323492 · Phase 4 · registry result, not featured evidence
11.7%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
18.6%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
10%
NCT01195467 · Phase 3 · registry result, not featured evidence
3.2%
NCT00625404 · Phase 3 · registry result, not featured evidence
20.3%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
10.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
25 mg DVR inserted once every 4 weeksa
metrorrhagia 55.1% (placebo 55.6%)
genitourinary chlamydia infection 20.5% (placebo 20.8%)
menorrhagia 19.7% (placebo 18.4%)
NCT01617096 · Phase 3 · monotherapy
show 9 more results
25 mg
infections 49.1%
reproductive system 20.9%
headache 3.5%
NCT02862171 · Phase 3
25 mg vaginal matrix ring
genitourinary chlamydia infection 8.4%
vaginal discharge 8%
vulvovaginitis trichomonal 5.9%
NCT02858037 · Phase 3 · registry result, not featured evidence
any event in soc 58.5%
any event in soc 32.4%
creatinine renal clearance decreased 30.3%
NCT03593655 · Phase 2 · registry result, not featured evidence
metrorrhagia 20.5% (placebo 26.1%)
vaginal discharge 15.1% (placebo 34.8%)
bacterial vaginosis 12.3% (placebo 8.7%)
NCT02028338 · Phase 2 · registry result, not featured evidence
vaginal discharge 11.1% (placebo 12.5%)
upper respiratory tract infection 8.3% (placebo 12.5%)
vaginal odour 6.9% (placebo 0%)
NCT02010593 · Phase 2 · registry result, not featured evidence
vaginitis bacterial 16.3% (placebo 11.9%)
vaginal candidiasis 9.3% (placebo 0%)
abdominal pain lower 4.7% (placebo 0%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
vaginitis bacterial 34.9% (placebo 11.9%)
vulvovaginal pruritus 9.3% (placebo 4.8%)
headache 7% (placebo 7.1%)
NCT00799058 · Phase 1/2 · registry result, not featured evidence
diarrhoea 11.1% (placebo 22.2%)
insomnia 11.1% (placebo 0%)
anal pruritus 5.6% (placebo 0%)
NCT03239483 · Phase 1 · registry result, not featured evidence
gynaecological chlamydia infection 32.7% (placebo 32.7%)
metrorrhagia 27% (placebo 29.6%)
genital infection female 23% (placebo 19.3%)
NCT01539226 · Phase na · registry result, not featured evidence
a
pharyngitis 20.2% (placebo 22.9%)
parasitic infection intestinal 18.8% (placebo 17.6%)
alanine aminotransferase increased 12.3% (placebo 12.6%)
NCT00458393 · Phase 3
show 13 more results
erectile dysfunction 4.8%
gastroenteritis 4.8%
headache 4.8%
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
gastroenteritis 5.3%
pulmonary embolism 5.3%
anxiety 0%
NCT02401230 · Phase 4 · registry result, not featured evidence
neutrophil count decreased 38%
blood albumin decreased 35.6%
blood sodium decreased 34%
NCT01380080 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 9%
diarrhea 8.4%
cough 5.2%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 9.7%
abdominal pain 4.2%
bronchitis 4.2%
NCT00323492 · Phase 4 · registry result, not featured evidence
100 mg
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · registry result, not featured evidence
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 22.1%
jaundice 22.1%
ocular icterus 20.1%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
bilateral arm pain 2.5%
cellulitis 2.5%
diarrhoea 2.5%
NCT01195467 · Phase 3 · registry result, not featured evidence
blood phosphorus decreased 19.4% (placebo 18.3%)
aspartate aminotransferase increased 13.1% (placebo 11.5%)
headache 13.1% (placebo 14.3%)
NCT00625404 · Phase 3 · registry result, not featured evidence
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3 · registry result, not featured evidence
cough 23.1%
neutrophil count decreased 23.1%
rash 23.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 27.3%
rash 26.5%
cough 24.1%
NCT00089505 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dapivirine

HIV-1 Incidence Rate Per 100 PY 2.7 count @ 56.5wk25 mg vaginal matrix ring
event rate · count
No placebo or comparator arm
NCT02858037 · Phase 3 · registry result, not featured evidence
HIV-2 Seroconversion 0% (n=1302) vs 0% (n=650) placebo @ 104wk
event count · % of participants
NCT01539226 · Phase na · registry result, not featured evidence · converted to % from 0 Participants as posted

Emtricitabine/tenofovir disoproxil fumarate

Cumulative Incidence of Death 4.8 vs 5.2 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
Cumulative Incidence of Disease Progression 16.6 vs 11.3 IPT Cumulative probability per 100 persons @ 96wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV Disease Progression 17.1 vs 12.5 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
show 1 more result
19.3 vs 15.3 IPT Cumulative probability per 100 persons @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies 0% (n=424) vs 0.01% (n=426) IPT @ 0wk
event count · % of participants
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
0.46% (n=424) vs 0.49% (n=426) IPT @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.84% (n=424) vs 0.85% (n=426) IPT @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.87% (n=424) vs 0.89% (n=426) IPT @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
CD4+ Cell 18 vs 19 IPT cells/uL @ 0wk
event count · cells/uL
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
74 vs 76 IPT cells/uL @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
121 vs 121 IPT cells/uL @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
176 vs 172 IPT cells/uL @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
CD4+ 192.7 vs 185.6 Daurunavir + Ritonavir cells/uL @ 48wk100 mg
absolute change · cells/uL
NCT02275780 · Phase 3 · registry result, not featured evidence
show 13 more results
224.1 vs 206.7 Daurunavir + Ritonavir cells/uL @ 96wk100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
49 vs 54 IPT cells/uL @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
96 vs 102 IPT cells/uL @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
158 vs 146 IPT cells/uL @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
8 vs 34 ABC/3TC cells/uL @ 48wk
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
213 vs 219 ATV+RTV+FTC/TDF cells/uL @ 48wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
277 vs 287 ATV+RTV+FTC/TDF cells/uL @ 96wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
310 vs 332 ATV+RTV+FTC/TDF cells/uL @ 144wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
350 vs 343 ATV+RTV+FTC/TDF cells/uL @ 192wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
191 vs 201 LPV/r cells/uL @ 48wk
NCT00089505 · Phase 3 · registry result, not featured evidence
172 vs 201 LPV/r cells/uL @ 48wk
NCT00089505 · Phase 3 · registry result, not featured evidence
291 vs 278 LPV/r cells/uL @ 96wk
NCT00089505 · Phase 3 · registry result, not featured evidence
223 vs 278 LPV/r cells/uL @ 96wk
NCT00089505 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 86.4% (n=154) vs 83.3% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
99.2% (n=154) vs 97.2% (n=156) ABC/3TC @ 48wk
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA LT 50 Copies 93% (n=154) vs 91.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA LT 200 Copies 84.4% (n=154) vs 82.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 79.9% (n=154) vs 77.6% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
Peak VO2 Change mL/Min 2.2 vs 2.8 Combivir or Trizivir kg @ 24wk200/300 mg, Daily, by Mouth
absolute change · kg
NCT00960622 · Phase 4 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 83.8% (n=383) vs 79.9% (n=383) Daurunavir + Ritonavir @ 48wk100 mg
responder rate · % of participants
NCT02275780 · Phase 3 · registry result, not featured evidence
show 5 more results
73.1% (n=379) vs 66% (n=376) Daurunavir + Ritonavir @ 96wk100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
85.2% (n=344) vs 87.4% (n=348) ATV+RTV+FTC/TDF @ 48wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
77.9% (n=344) vs 79.3% (n=348) ATV+RTV+FTC/TDF @ 96wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
72.1% (n=344) vs 74.1% (n=348) ATV+RTV+FTC/TDF @ 144wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
71.6% (n=74) vs 79.7% (n=69) ATV+RTV+FTC/TDF @ 192wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapivirine's landscape · Emtricitabine/tenofovir disoproxil fumarate's landscape